The Effect of Ferric Carboxymaltose on Fibroblast Growth Factor 23 (FGF23) in Children with Iron Deficiency Anemia Due to Gastrointestinal Diseases

The Effect of Ferric Carboxymaltose on Fibroblast Growth Factor 23 (FGF23) in Children with Iron Deficiency Anemia Due to Gastrointestinal Diseases

<b>Background:</b> Hypophosphatemia is a known side-effect of parenteral iron administration, especially after intravenous ferric carboxymaltose (FCM). Fibroblast growth factor 23 (FGF23) is thought to play an important role in the pathophysiology of serum phosphate homeostasis. This stu...

Full description

Saved in:
Bibliographic Details
Main Authors: Maria Ntoumpara, Elpis Mantadakis, Lemonia Skoura, Paraskevi Panagopoulou, Elpida Emmanouilidou-Fotoulaki, Eleftheria Parasidou, Paraskevoula Koutra, Maria Fotoulaki
Format: Article
Language:English
Published: MDPI AG 2024-11-01
Series:Hemato
Subjects:
iron deficiency
iron deficiency anemia
parenteral iron
ferric carboxymaltose
fibrobast growth factor 23
hypophosphatemia
Online Access:https://www.mdpi.com/2673-6357/5/4/34
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items